Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer
- Sponsor
- Yung NA
- Study ID
- NCT07310433
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Metastatic Prostate Cancer
- Prostate Cancer
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Dapagliflozin (10mg Tab) — DRUGDapagliflozin (10mg Tab)
- standard medical care (ADT + NHA) — DRUGstandard medical care for metastatic prostate cancer (ADT + NHA), the choice of NHA and ADT to be agreed among participant and treating physician with dosage and frequency according to local guideline. Surgical castration is also acceptable as ADT.
Study Details
Dapagliflozin is a well-established medication being marketed and used for treatment Type 2 diabetes mellitus (T2DM). In retrospective cohort studies done by our team, we found that metastatic prostate cancer patients who received Dapagliflozin together with standard anti-cancer treatment, androgen deprivation therapy (ADT) combined with novel hormonal agent (NHA), had better tumor control than those having ADT and NHA.
Key Dates
- Start date
- Jun 1, 2026
- Status verified
- Dec 2025
- Primary completion
- Oct 30, 2029
- Completion
- Oct 30, 2030
Study Design
- Enrollment
- 60 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Interventiondapagliflozin 10 mg daily along with standard medical care (NHA + ADT)
- Active Comparator: ControlStandard of Care (ADT + NHA)
Primary Outcome Measure
Progression free survival [ Time Frame: From date of randomization until the date of first disease progression per RECIST 1.1 criteria, assessed up to 60 months ]
Central Contacts
- Study Coordinator852-22554852
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Use of Tracking Devices to Locate Abnormalities During Invasive ProceduresEnrolling By Invitation · National Institutes of Health Clinical Center (CC) · Bethesda, Maryland
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate CancerRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey